Article

Biologics in oral medicine: oral Crohn's disease and orofacial granulomatosis.

Centre d'Affaires Poincaré, Rue Poincaré, Nice, France WHO Collaborating Centre for Oral Health-General Health, Oral Medicine, Bristol.
Oral Diseases (impact factor: 2.49). 03/2012; 18(7):633-8. DOI:10.1111/j.1601-0825.2012.01918.x pp.633-8
Source: PubMed

ABSTRACT Oral Diseases (2012) 18, 633-638 Antitumour necrosis factor (TNF-α) therapy has a potential to benefit patients with oral lesions of Crohn's disease (CD) and patients with orofacial granulomatosis (OFG). The most appropriate use would appear to be in patients with severe or multisystem features, where other available agents have failed or have been associated with adverse effects. TNF-α antagonists (infliximab in particular) have a role in the management of orofacial CD and OFG, but potential adverse effects of TNF-α antagonists include acute infusion reactions, infection and increased risk of malignancy. Thus, a full risk-benefit analysis is indicated, with patient selection, use and subsequent monitoring coordinated with gastroenterologists with appropriate training and experience in biological therapies.

0 0
 · 
1 Bookmark
 · 
38 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

633-638 Antitumour necrosis factor
 
acute infusion reactions
 
adverse effects
 
available agents
 
benefit patients
 
Crohn's disease
 
full risk-benefit analysis
 
gastroenterologists
 
multisystem features
 
Oral Diseases
 
oral lesions
 
orofacial CD
 
orofacial granulomatosis
 
patients
 
potential adverse effects
 
TNF-α
 
TNF-α antagonists
 

Id O'Neill